TY - JOUR
T1 - Frequency, morbidity and equity - the case for increased research on male fertility
AU - Kimmins, S
AU - Anderson, RA
AU - Barratt, CLR
AU - Behre, HM
AU - Catford, SR
AU - De, Jonge CJ
AU - Delbes, G
AU - Eisenberg, ML
AU - Garrido, N
AU - Houston, BJ
AU - Jørgensen, N
AU - Krausz, C
AU - O'Bryan, MK
PY - 2024/2
Y1 - 2024/2
N2 - Currently, most men with infertility cannot be given an aetiology, which reflects a lack of knowledge around gamete production and how it is affected by genetics and the environment. A failure to recognize the burden of male infertility and its potential as a biomarker for systemic illness exists. The absence of such knowledge results in patients generally being treated as a uniform group, for whom the strategy is to bypass the causality using medically assisted reproduction (MAR) techniques. In doing so, opportunities to prevent co-morbidity are missed and the burden of MAR is shifted to the woman. To advance understanding of men’s reproductive health, longitudinal and multi-national centres for data and sample collection are essential. Such programmes must enable an integrated view of the consequences of genetics, epigenetics and environmental factors on fertility and offspring health. Definition and possible amelioration of the consequences of MAR for conceived children are needed. Inherent in this statement is the necessity to promote fertility restoration and/or use the least invasive MAR strategy available. To achieve this aim, protocols must be rigorously tested and the move towards personalized medicine encouraged. Equally, education of the public, governments and clinicians on the frequency and consequences of infertility is needed. Health options, including male contraceptives, must be expanded, and the opportunities encompassed in such investment understood. The pressing questions related to male reproductive health, spanning the spectrum of andrology are identified in the Expert Recommendation.
AB - Currently, most men with infertility cannot be given an aetiology, which reflects a lack of knowledge around gamete production and how it is affected by genetics and the environment. A failure to recognize the burden of male infertility and its potential as a biomarker for systemic illness exists. The absence of such knowledge results in patients generally being treated as a uniform group, for whom the strategy is to bypass the causality using medically assisted reproduction (MAR) techniques. In doing so, opportunities to prevent co-morbidity are missed and the burden of MAR is shifted to the woman. To advance understanding of men’s reproductive health, longitudinal and multi-national centres for data and sample collection are essential. Such programmes must enable an integrated view of the consequences of genetics, epigenetics and environmental factors on fertility and offspring health. Definition and possible amelioration of the consequences of MAR for conceived children are needed. Inherent in this statement is the necessity to promote fertility restoration and/or use the least invasive MAR strategy available. To achieve this aim, protocols must be rigorously tested and the move towards personalized medicine encouraged. Equally, education of the public, governments and clinicians on the frequency and consequences of infertility is needed. Health options, including male contraceptives, must be expanded, and the opportunities encompassed in such investment understood. The pressing questions related to male reproductive health, spanning the spectrum of andrology are identified in the Expert Recommendation.
KW - Child
KW - Female
KW - Fertility
KW - Humans
KW - Infertility, Male/epidemiology
KW - Male
KW - Men's Health
KW - Morbidity
KW - Reproductive Techniques, Assisted
UR - http://europepmc.org/abstract/med/37828407
UR - http://www.scopus.com/inward/record.url?scp=85174049319&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/97d74b00-f3bc-3966-835b-5a6889755364/
U2 - 10.1038/s41585-023-00820-4
DO - 10.1038/s41585-023-00820-4
M3 - Review article
C2 - 37828407
SN - 1759-4812
VL - 21
SP - 102
EP - 124
JO - Nature Reviews. Urology
JF - Nature Reviews. Urology
IS - 2
ER -